C4 Therapeutics (CCCC) Insider Owen Hughes Buys 62,000 Shares
Insider Owen Hughes purchased 62,000 shares of C4 Therapeutics on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Owen Hughes bought 62,000 shares of C4 Therapeutics, Inc. ($CCCC) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CCCC is up 2.1% after 1 week, down 20.0% after 1 month and down 34.8% to date (from the $4.25 close on Jun 24, 2026).
CCCC
C4 Therapeutics, Inc.
Key Points
- Owen Hughes bought 62,000 shares of C4 Therapeutics, Inc. valued at around $272,800 based on the current price of $4.4 on June 24, 2026.
- C4 Therapeutics has seen a strong insider trading activity, with multiple executives buying the same number of shares on the same day, indicating a collective confidence in the company's direction.
- Analysts have recently given C4 Therapeutics an 'Overweight' rating with a target price of $10.00, suggesting potential growth in the stock.
Get $CCCC trade alerts by text
We text you when insiders, Congress or big funds trade $CCCC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated C4 Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at C4 Therapeutics, Inc.
Owen Hughes bought 62,000 shares of C4 Therapeutics, Inc. (NasdaqGS: CCCC) on June 24, 2026. This purchase is valued at approximately $272,800, based on the current price of $4.4 per share.
Multiple Insiders Buy Shares
Hughes wasn't the only one making moves on this day. Other insiders, including Ronald Cooper, Utpal Koppikar, Donna Roy Grogan, Stephen Fawell, Laura Bessen, and Steven Hoerter, each purchased 62,000 shares on June 24, 2026. This collective buying action suggests a strong belief in the future of C4 Therapeutics.
How C4 Therapeutics, Inc. Stock Has Traded
C4 Therapeutics shares are currently trading at $4.4, showing a notable increase from the 52-week low of $1.69. The stock's price is also above its 50-day moving average of $3.74, indicating positive momentum. With analysts setting a mean target price of $10, there could be considerable room for growth.
Analysts Set New Price Targets
On October 9, 2026, JP Morgan initiated coverage of C4 Therapeutics with an 'Overweight' rating and a price target of $10. This rating reflects a positive sentiment from analysts, who see potential in the company's clinical-stage products.
About C4 Therapeutics
C4 Therapeutics, based in Watertown, Massachusetts, focuses on developing innovative therapies that target disease-causing proteins. Its lead candidate, Cemsidomide, aims to treat multiple myeloma, while it is also working on therapies for various cancers. The recent insider purchases may indicate confidence in these ongoing developments.
What's Ahead for C4 Therapeutics, Inc.
The next earnings report for C4 Therapeutics is scheduled for November 5, 2026. This upcoming report will be crucial for investors to gauge the company's financial health and progress in its drug development pipeline. As always, keep in mind that the 13F filings reflect past holdings and may not represent current positions.
Related Filing Alerts
Source: Owen Hughes's Form 4 filing on $CCCC (Jun 24, 2026). Find the original filing: CCCC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts